<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="and underlying malignancy. It is well-established that rituximab-containing regimens, mainly" exact="rituximab" post="with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), are strongly"/>
 <result pre="that rituximab-containing regimens, mainly rituximab with cyclophosphamide, doxorubicin, vincristine, and" exact="prednisone" post="(R-CHOP), are strongly linked to a high risk of"/>
 <result pre="malignancy: A meta-analysisHepatology (Baltimore, Md.)20176637938810.1002/hep.29082 11.HuangYHet al.Randomized controlled trial of" exact="entecavir" post="prophylaxis for rituximab-associated hepatitis B virus reactivation in patients"/>
 <result pre="therapyGastroenterology2015148221244.e22310.1053/j.gastro.2014.10.03825447852 19.Inayat, F. et al. Hepatitis B virus reactivation following" exact="imatinib" post="therapy: A comparative review of 9 cases. Journal of"/>
 <result pre="B virus reactivation in a chronic myeloid leukemia patient during" exact="imatinib" post="mesylate treatmentLeukemia &amp;amp; lymphoma20064715515710.1080/1463923050023681816321842 22.KangBWet al.Chronic myeloid leukemia patient"/>
 <result pre="patient manifesting fatal hepatitis B virus reactivation during treatment with" exact="imatinib" post="rescued by liver transplantation: case report and literature reviewInternational"/>
 <result pre="with the hepatitis B virus immune escape mutant G145R during" exact="dasatinib" post="treatment for chronic myeloid leukemiaInternational journal of hematology201510237938210.1007/s12185-015-1788-y25842192 24.ThiaTJTanHHChuahTHChowWCLuiHFImatinib"/>
</results>
